CCJ Cameco Corporation
QT18| Index | — | P/E | 124.37 | EPS (ttm) | 0.59 | Insider Own | — | Shs Outstand | 435.53M | Perf Week | -7.20% |
| Market Cap | 31.96B | Forward P/E | 40.37 | EPS next Y | 1.82 | Insider Trans | — | Shs Float | 434.48M | Perf Month | -13.85% |
| Enterprise Value | 31.89B | PEG | 3.14 | EPS next Q | 0.17 | Short Float | 2.10% | Perf Quarter | -21.17% | ||
| Income | 257.00M | P/S | 12.73 | EPS this Y | -4.80% | Short Ratio | 2.87 | Perf Half Y | -37.95% | ||
| Sales | 2.51B | P/B | 6.37 | EPS next Y | 86.22% | ROA | 3.45% | Short Interest | 9.11M | Perf YTD | -19.79% |
| Book/sh | 11.52 | P/C | 40.82 | EPS next 5Y | 39.64% | ROE | 5.09% | 52W High | 135.24 -45.74% | Perf Year | -29.93% |
| Cash/sh | 1.80 | P/FCF | 83.44 | EPS past 3/5Y | 78.78% — | ROIC | 3.93% | 52W Low | 73.26 0.16% | Perf 3Y | 91.34% |
| Dividend Est. | 0.17 (0.23%) | EV/EBITDA | 51.68 | Sales past 3/5Y | 20.14% 13.18% | Gross Margin | 27.57% | Volatility | 3.94% 3.48% | Perf 5Y | 176.91% |
| Dividend TTM | 0.17 (0.23%) | EV/Sales | 12.70 | EPS Y/Y TTM | -32.89% | Oper. Margin | 14.26% | ATR (14) | 3.64 | Perf 10Y | 812.69% |
| Dividend Ex-Date | Dec 01, 2025 | Quick Ratio | 2.10 | Sales Y/Y TTM | -1.76% | Profit Margin | 10.21% | RSI (14) | 31.00 | Recom | 2.38 |
| Dividend Gr. 3/5Y | 25.01% 23.02% | Current Ratio | 3.06 | EPS Q/Q | — | SMA20 | -11.36% | Beta | 1.19 | Target Price | 135.00 |
| Payout | 29.44% | Debt/Eq | 0.14 | Sales Q/Q | -7.11% | SMA50 | -18.49% | Rel Volume | 1.53 | Prev Close | 76.91 |
| Employees | 3,082 | LT Debt/Eq | 0.14 | Earnings | Feb 12 | SMA200 | -29.50% | Avg Volume | 3.09M | Price | 73.38 |
| IPO Date | Mar 14, 1996 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -101.40% -18.23% | Net Debt/EBITDA | -0.12 | Volume | 4,716,258 | Change | -4.59% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-22-26 | Reiterated | Truist Securities | Buy | $130 → $125 |
| Oct-19-26 | Reiterated | Barclays | Equal Weight | $97 → $95 |
| Sep-03-26 | Initiated | Jefferies | Buy | $138 |
| Aug-12-26 | Reiterated | Truist Securities | Buy | $129 → $130 |
| Aug-04-26 | Reiterated | Barclays | Equal Weight | $104 → $97 |
| Jul-13-26 | Initiated | Truist | Buy | $129 |
| Jun-15-26 | Reiterated | Bernstein | $147 → $135 | |
| May-21-26 | Initiated | Barclays | Equal Weight | $108 |
| May-06-26 | Reiterated | Scotiabank | Outperform | $150 → $175 |
| Feb-05-26 | Reiterated | Bernstein | $101 → $147 |
Cameco Corporation is a prominent global enterprise specializing in the production and distribution of uranium. Its operations are structured into two core divisions: Uranium and Fuel Services. The Uranium division manages the full upstream process, encompassing the exploration, extraction, and initial processing (milling) of uranium ore, as well as the procurement and sale of uranium concentrate. Conversely, the Fuel Services division focuses on the downstream transformation of uranium. This includes the refining, conversion, and fabrication of uranium concentrate into usable forms, alongside providing related conversion services. Furthermore, this segment is responsible for manufacturing specialized fuel bundles and reactor components specifically designed for CANDU reactors. Cameco provides its essential uranium products and associated fuel services to nuclear utility clients across major international markets, including the Americas, Europe, and Asia. The company was founded in 1987 and maintains its principal office in Saskatoon, Canada.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,511 | 2,490 | 2,289 | 1,918 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,809 | 1,824 | 1,513 | 1,338 | — | — | — | — | — | |
| Gross Profit | 702 | 665 | 776 | 580 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 263 | 223 | 199 | 182 | — | — | — | — | — | |
| Research and Development | 35 | 28 | 27 | 16 | — | — | — | — | — | |
| Other Operating Expense | 38 | -1 | 178 | 172 | — | — | — | — | — | |
| Operating Income | 366 | 415 | 372 | 210 | — | — | — | — | — | |
| Interest Expense | 58 | 53 | 81 | 57 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 32 | 194 | -104 | 208 | — | — | — | — | — | |
| Net Income Before Taxes | 340 | 556 | 187 | 361 | — | — | — | — | — | |
| Income Taxes | 84 | 134 | 62 | 94 | — | — | — | — | — | |
| Consolidated Net Income | 257 | 422 | 125 | 267 | — | — | — | — | — | |
| Net Income From Continuing Operations | 256 | 422 | 125 | 267 | — | — | — | — | — | |
| Net Income | 257 | 422 | 125 | 267 | — | — | — | — | — | |
| EPS (Recurring) | 0.59 | 0.97 | 0.29 | 0.62 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.59 | 0.97 | 0.29 | 0.62 | — | — | — | — | — | |
| EPS (Diluted) | 0.59 | 0.97 | 0.28 | 0.62 | — | — | — | — | — | |
| EBITDA | 617 | 819 | 552 | 593 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 124.37 | 94.69 | 180.49 | 70.06 | — | — | — | — | — | |
| Price To Sales Ratio | 12.74 | 15.98 | 9.77 | 9.73 | — | — | — | — | — | |
| Gross Margin | 27.96 | 26.71 | 33.90 | 30.24 | — | — | — | — | — | |
| Operating Margin | 14.58 | 16.67 | 16.25 | 10.95 | — | — | — | — | — | |
| Net Margin | 10.23 | 16.95 | 5.46 | 13.92 | — | — | — | — | — | |
| Shares Outstanding | 436 | 435 | 435 | 433 | — | — | — | — | — | |
| Market Capitalization | 31,994 | 39,798 | 22,355 | 18,662 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |